Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.57
WX's Cash to Debt is ranked lower than
61% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.71 vs. WX: 1.57 )
Ranked among companies with meaningful Cash to Debt only.
WX' s 10-Year Cash to Debt Range
Min: 0.33  Med: 3.47 Max: N/A
Current: 1.57
Equity to Asset 0.66
WX's Equity to Asset is ranked higher than
58% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. WX: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
WX' s 10-Year Equity to Asset Range
Min: -0.32  Med: 0.73 Max: 0.8
Current: 0.66
-0.32
0.8
Interest Coverage 40.19
WX's Interest Coverage is ranked lower than
66% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10000.00 vs. WX: 40.19 )
Ranked among companies with meaningful Interest Coverage only.
WX' s 10-Year Interest Coverage Range
Min: 6.71  Med: 48.81 Max: 9999.99
Current: 40.19
6.71
9999.99
F-Score: 3
Z-Score: 6.13
WACC vs ROIC
8.15%
15.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.75
WX's Operating margin (%) is ranked higher than
85% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. WX: 13.75 )
Ranked among companies with meaningful Operating margin (%) only.
WX' s 10-Year Operating margin (%) Range
Min: -8.26  Med: 18.56 Max: 25.87
Current: 13.75
-8.26
25.87
Net-margin (%) 15.85
WX's Net-margin (%) is ranked higher than
92% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. WX: 15.85 )
Ranked among companies with meaningful Net-margin (%) only.
WX' s 10-Year Net-margin (%) Range
Min: -25.33  Med: 18.14 Max: 27.18
Current: 15.85
-25.33
27.18
ROE (%) 15.03
WX's ROE (%) is ranked higher than
83% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.85 vs. WX: 15.03 )
Ranked among companies with meaningful ROE (%) only.
WX' s 10-Year ROE (%) Range
Min: -26.63  Med: 20.69 Max: 226.96
Current: 15.03
-26.63
226.96
ROA (%) 10.48
WX's ROA (%) is ranked higher than
85% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. WX: 10.48 )
Ranked among companies with meaningful ROA (%) only.
WX' s 10-Year ROA (%) Range
Min: -18.88  Med: 13.99 Max: 72.95
Current: 10.48
-18.88
72.95
ROC (Joel Greenblatt) (%) 33.66
WX's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. WX: 33.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
WX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14.87  Med: 35.88 Max: 71.72
Current: 33.66
-14.87
71.72
Revenue Growth (3Y)(%) 20.10
WX's Revenue Growth (3Y)(%) is ranked higher than
88% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. WX: 20.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
WX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 10.8  Med: 23.20 Max: 159.6
Current: 20.1
10.8
159.6
EBITDA Growth (3Y)(%) 13.70
WX's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. WX: 13.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
WX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 21.00 Max: 102.7
Current: 13.7
0
102.7
EPS Growth (3Y)(%) 13.40
WX's EPS Growth (3Y)(%) is ranked higher than
73% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. WX: 13.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
WX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 11.10 Max: 45
Current: 13.4
0
45
» WX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

WX Guru Trades in Q2 2014

Jim Simons 127,500 sh (+13.03%)
Columbia Wanger 3,361,141 sh (+0.79%)
Mario Gabelli 57,200 sh (-4.19%)
Ron Baron 201,500 sh (-4.28%)
Sarah Ketterer 126,000 sh (-20.00%)
» More
Q3 2014

WX Guru Trades in Q3 2014

Jim Simons 235,300 sh (+84.55%)
Sarah Ketterer 180,700 sh (+43.41%)
Ron Baron 201,500 sh (unchged)
Mario Gabelli 57,200 sh (unchged)
Columbia Wanger 3,348,020 sh (-0.39%)
» More
Q4 2014

WX Guru Trades in Q4 2014

Ron Baron 251,500 sh (+24.81%)
Sarah Ketterer 180,700 sh (unchged)
Mario Gabelli 57,200 sh (unchged)
Columbia Wanger 3,334,742 sh (-0.40%)
Jim Simons 119,200 sh (-49.34%)
» More
Q1 2015

WX Guru Trades in Q1 2015

Matthews Pacific Tiger Fund 2,243,158 sh (New)
Ron Baron 341,500 sh (+35.79%)
Mario Gabelli 57,200 sh (unchged)
Sarah Ketterer 105,600 sh (-41.56%)
Jim Simons 55,400 sh (-53.52%)
Columbia Wanger 1,147,000 sh (-65.60%)
» More
» Details

Insider Trades

Latest Guru Trades with WX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on WuXi PharmaTech (Cayman) Inc

Baron Funds Comments on WuXi PharmaTech - Feb 24, 2014

Shares of WuXi PharmaTech (Cayman) Inc. (WX) were strong in the fourth quarter. As the largest Chinese Contract Research Organization (CRO), with an estimated 27% market share, WuXi is a beneficiary of increased pharma outsourcing activity to countries like China and India. Performance during the fourth quarter is attributable to above consensus financial results and a growing pipeline of contract research and manufacturing activity. We retain conviction in the company due to its high growth potential and strong relationships with leading pharmaceutical companies. (Anuj Aggarwal)

From Ron Baron (Trades, Portfolio)'s Baron Funds' fourth quarter 2013 commentary.

Check out Ron Baron latest stock trades

Top Ranked Articles about WuXi PharmaTech (Cayman) Inc

Matthews Pacific Tiger Fund Adds 2 New Stocks to Portfolio
The Matthews Pacific Tiger Fund (Trades, Portfolio) added two new stocks to the portfolio, while divesting two others during the first quarter of 2015, according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.96
WX's P/E(ttm) is ranked higher than
60% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. WX: 26.96 )
Ranked among companies with meaningful P/E(ttm) only.
WX' s 10-Year P/E(ttm) Range
Min: 6.67  Med: 16.89 Max: 103.94
Current: 26.96
6.67
103.94
Forward P/E 23.47
WX's Forward P/E is ranked lower than
62% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.16 vs. WX: 23.47 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.30
WX's PE(NRI) is ranked higher than
61% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. WX: 27.30 )
Ranked among companies with meaningful PE(NRI) only.
WX' s 10-Year PE(NRI) Range
Min: 6.62  Med: 16.76 Max: 102.94
Current: 27.3
6.62
102.94
P/B 3.74
WX's P/B is ranked lower than
56% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. WX: 3.74 )
Ranked among companies with meaningful P/B only.
WX' s 10-Year P/B Range
Min: 1.11  Med: 3.10 Max: 10.64
Current: 3.74
1.11
10.64
P/S 4.28
WX's P/S is ranked lower than
62% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. WX: 4.28 )
Ranked among companies with meaningful P/S only.
WX' s 10-Year P/S Range
Min: 0.79  Med: 3.45 Max: 11.05
Current: 4.28
0.79
11.05
EV-to-EBIT 21.86
WX's EV-to-EBIT is ranked higher than
51% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.19 vs. WX: 21.86 )
Ranked among companies with meaningful EV-to-EBIT only.
WX' s 10-Year EV-to-EBIT Range
Min: -107.1  Med: 16.65 Max: 146.9
Current: 21.86
-107.1
146.9
PEG 1.66
WX's PEG is ranked higher than
74% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. WX: 1.66 )
Ranked among companies with meaningful PEG only.
WX' s 10-Year PEG Range
Min: 1.64  Med: 3.82 Max: 4.41
Current: 1.66
1.64
4.41
Shiller P/E 27.48
WX's Shiller P/E is ranked higher than
53% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.25 vs. WX: 27.48 )
Ranked among companies with meaningful Shiller P/E only.
WX' s 10-Year Shiller P/E Range
Min: 18.48  Med: 28.91 Max: 64.93
Current: 27.48
18.48
64.93
Current Ratio 2.35
WX's Current Ratio is ranked lower than
56% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. WX: 2.35 )
Ranked among companies with meaningful Current Ratio only.
WX' s 10-Year Current Ratio Range
Min: 0.79  Med: 2.64 Max: 5.75
Current: 2.35
0.79
5.75
Quick Ratio 2.17
WX's Quick Ratio is ranked lower than
54% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. WX: 2.17 )
Ranked among companies with meaningful Quick Ratio only.
WX' s 10-Year Quick Ratio Range
Min: 0.6  Med: 2.33 Max: 5.45
Current: 2.17
0.6
5.45
Days Inventory 36.92
WX's Days Inventory is ranked higher than
66% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.61 vs. WX: 36.92 )
Ranked among companies with meaningful Days Inventory only.
WX' s 10-Year Days Inventory Range
Min: 23.55  Med: 43.02 Max: 66.63
Current: 36.92
23.55
66.63
Days Sales Outstanding 81.22
WX's Days Sales Outstanding is ranked lower than
65% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. WX: 81.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
WX' s 10-Year Days Sales Outstanding Range
Min: 47.86  Med: 63.76 Max: 88.2
Current: 81.22
47.86
88.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 14.28
WX's Price/Net Current Asset Value is ranked lower than
76% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.29 vs. WX: 14.28 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
WX' s 10-Year Price/Net Current Asset Value Range
Min: 4.31  Med: 8.11 Max: 61.52
Current: 14.28
4.31
61.52
Price/Tangible Book 4.64
WX's Price/Tangible Book is ranked higher than
53% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.08 vs. WX: 4.64 )
Ranked among companies with meaningful Price/Tangible Book only.
WX' s 10-Year Price/Tangible Book Range
Min: 1.45  Med: 3.36 Max: 9.09
Current: 4.64
1.45
9.09
Price/Projected FCF 4.75
WX's Price/Projected FCF is ranked lower than
61% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. WX: 4.75 )
Ranked among companies with meaningful Price/Projected FCF only.
WX' s 10-Year Price/Projected FCF Range
Min: 1.15  Med: 1.82 Max: 2.33
Current: 4.75
1.15
2.33
Price/Median PS Value 1.24
WX's Price/Median PS Value is ranked lower than
60% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. WX: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
WX' s 10-Year Price/Median PS Value Range
Min: 0.28  Med: 1.04 Max: 2.62
Current: 1.24
0.28
2.62
Price/Peter Lynch Fair Value 2.01
WX's Price/Peter Lynch Fair Value is ranked higher than
52% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. WX: 2.01 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
WX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.25  Med: 0.54 Max: 4.32
Current: 2.01
0.25
4.32
Price/Graham Number 2.35
WX's Price/Graham Number is ranked higher than
61% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. WX: 2.35 )
Ranked among companies with meaningful Price/Graham Number only.
WX' s 10-Year Price/Graham Number Range
Min: 0.86  Med: 1.77 Max: 4.93
Current: 2.35
0.86
4.93
Earnings Yield (Greenblatt) (%) 4.67
WX's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. WX: 4.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
WX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 5.50 Max: 12
Current: 4.67
0.7
12
Forward Rate of Return (Yacktman) (%) 13.39
WX's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.17 vs. WX: 13.39 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
WX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.2  Med: 2.35 Max: 15.9
Current: 13.39
0.2
15.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:3W11.Germany,
WuXi PharmaTech (Cayman) Inc was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes biocompatibility or safe
» More Articles for WX

Headlines

Articles On GuruFocus.com
Matthews Pacific Tiger Fund Adds 2 New Stocks to Portfolio May 05 2015 
Baron Funds Comments on WuXi PharmaTech Feb 24 2014 
Columbia Management's Top 5 New Buys Amid Buoyant Outlook Aug 12 2013 
comment on WX Sep 15 2012 
Stocks That Are Cheaper Than Julian Robertson Bought Jan 06 2012 
Stocks That Julian Robertson Keeps Buying Dec 23 2011 
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Tiger Management Buys WX, CVC, THRX, Sells Apple Inc., Google Inc., Ebay Inc. Nov 15 2010 
WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services Dec 09 2008 

More From Other Websites
Chinese Consortium Enters into Agreement to Acquire Ambrx Jun 19 2015
Qihoo Gets $9 Billion Buyout Offer From CEO Jun 17 2015
Decade Capital’s Small-Cap Health Stock Picks Appear Primed For Growth Jun 14 2015
REGENXBIO Enters Into Strategic Manufacturing Collaboration With Wuxi Apptec Jun 11 2015
WuXi AppTec Partners with Fudan University and the Collaborative Innovation Center of Genetics and... Jun 04 2015
WuXi AppTec Partners with Fudan University and the Collaborative Innovation Center of Genetics and... Jun 04 2015
WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in Both Rare Disease and Cancer Jun 03 2015
WuXi AppTec Expands Investment in Instem Software Solutions Jun 03 2015
Fosun Pharma to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx May 22 2015
Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S.... May 21 2015
China Everbright Limited to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx May 21 2015
Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S.... May 21 2015
WuXi Launches e-Commerce Platform for Chemistry Products May 21 2015
WuXi Launches e-Commerce Platform for Chemistry Products May 21 2015
WuXi PharmaTech Call scheduled for 8:00 am ET today May 14 2015
WuXi PharmaTech Announces First-Quarter 2015 Results May 13 2015
WuXi PharmaTech Announces First-Quarter 2015 Results May 13 2015
WuXi PharmaTech Announces Formation of a Special Committee to Evaluate Non-Binding Proposal May 13 2015
WuXi PharmaTech Announces Formation of a Special Committee to Evaluate Non-Binding Proposal May 13 2015
Q1 2015 Wuxi Pharmatech Cayman Inc Earnings Release - After Market Close May 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK